The systemic sclerosis treatment market will expand from just under $316 million in 2014 to around $500 million by 2024, representing a modest compound annual growth rate (CAGR) of 4.7%, new research shows. According to research and consulting firm GlobalData’s latest report, this rise, spread across the seven major markets of the USA, Italy, France, the UK, Spain, Germany and Japan, will be driven by a number of factors, including an increased use of expensive biologics, and off-label use of therapies to treat the disease. Despite this, there has been renewed interest from pharmaceutical companies, and the pipeline will see some interesting developments over the forecast period. |
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze